Analysis of Revenues
Paying user area
Try for free
Johnson & Johnson pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Geographic Areas
- Enterprise Value to FCFF (EV/FCFF)
- Selected Financial Data since 2005
- Net Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Johnson & Johnson for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Johnson & Johnson, income statement, revenues
US$ in millions
| 12 months ended: | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | |||||||||||
| MedTech | |||||||||||
| Sales to customers |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Innovative Medicine Revenue
- The annual revenue in the Innovative Medicine segment initially increased from US$59,625 million in 2020 to US$66,715 million in 2021, continuing to rise slightly to US$67,516 million in 2022. However, a notable decline is observed in 2023, with revenue decreasing sharply to US$54,759 million, followed by a modest recovery to US$56,964 million in 2024. This pattern indicates a peak in 2022, a significant downturn the following year, and then a partial rebound.
- MedTech Revenue
- The MedTech segment displayed consistent growth across the observed periods. Revenue increased steadily from US$22,959 million in 2020 to US$27,060 million in 2021, followed by incremental gains to US$27,427 million in 2022, continuing up to US$30,400 million in 2023, and reaching US$31,857 million in 2024. The trend suggests a sustained expansion without any periods of decline.
- Total Sales to Customers
- Total sales to customers show an overall growth from US$82,584 million in 2020 to a peak of US$94,943 million in 2022. This was followed by a decline to US$85,159 million in 2023, with a subsequent increase to US$88,821 million in 2024. The pattern mirrors the trends seen in the Innovative Medicine segment, indicating that changes in this segment significantly influence total sales figures.
- Summary
- The data reflects two contrasting revenue dynamics: Innovative Medicine experienced growth followed by a sharp dip and a mild recovery, while MedTech consistently expanded throughout the period. Total sales largely tracked the Innovative Medicine segment's performance, showing a peak in 2022, a decrease in the subsequent year, and partial recovery thereafter. This suggests that the overall sales performance is more sensitive to fluctuations in the Innovative Medicine segment than in MedTech.